adamantane has been researched along with Diabetic Angiopathies in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bombelli, M; Dell'Oro, R; Gamba, P; Grassi, G; Maloberti, A; Mancia, G; Nicoli, F; Villa, P | 1 |
| Bhatt, DL; Braunwald, E; Davidson, J; Frederich, B; Hirshberg, B; Mosenzon, O; Ohman, P; Price, DL; Raz, I; Scirica, BM; Stahre, CI; Steg, PG; Udell, JA | 1 |
| Dhindsa, S; Jialal, I | 1 |
| Avogaro, A; Dardano, A; de Kreutzenberg, SV; Del Prato, S | 1 |
| Bhatt, DL; Bonnici, F; Braunwald, E; Cahn, A; Frederich, R; Hirshberg, B; Kumar, KM; Leiter, LA; Mosenzon, O; Raz, I; Scirica, BM; Smahelova, A; Stahre, C; Teoh, H | 1 |
| Fonseca, VA; John-Kalarickal, J; Wani, JH | 1 |
| Couturier, A; Dejager, S; Foley, JE; Kothny, W; Ligueros-Saylan, M; Schweizer, A | 1 |
| Maeda, S; Matsui, T; Yamagishi, S | 1 |
| Fisman, EZ; Goldenberg, I; Klempfner, R; Leor, J; Tenenbaum, A | 1 |
3 review(s) available for adamantane and Diabetic Angiopathies
| Article | Year |
|---|---|
Dipeptidyl peptidase-4 inhibitors can minimize the hypoglycaemic burden and enhance safety in elderly people with diabetes.
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Glycated Hemoglobin; Humans; Hypoglycemia; Nitriles; Practice Guidelines as Topic; Pyrrolidines; Quality of Life; Vildagliptin | 2015 |
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review.
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2008 |
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population.
Topics: Adamantane; Cerebrovascular Disorders; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Middle Aged; Nitriles; Pyrrolidines; Randomized Controlled Trials as Topic; Vildagliptin | 2010 |
3 trial(s) available for adamantane and Diabetic Angiopathies
| Article | Year |
|---|---|
Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Topics: Adamantane; Aged; Biomarkers; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Middle Aged; Overweight; Prevalence; Risk Factors; Severity of Illness Index | 2013 |
Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial.
Topics: Adamantane; Adult; Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycated Hemoglobin; Heart Failure; Hospitalization; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome | 2015 |
Effects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery disease.
Topics: Adamantane; Adiponectin; Atherosclerosis; Biomarkers; C-Reactive Protein; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Interleukin-1beta; Interleukin-6; Israel; Matrix Metalloproteinase 9; Metformin; Nitriles; Platelet Function Tests; Prospective Studies; Pyrrolidines; Research Design; Thrombosis; Time Factors; Treatment Outcome; Vildagliptin | 2012 |
3 other study(ies) available for adamantane and Diabetic Angiopathies
| Article | Year |
|---|---|
Long-term Saxagliptin Treatment Improves Endothelial Function but not Pulse Wave Velocity and Intima-Media Thickness in Type 2 Diabetic Patients.
Topics: Adamantane; Biomarkers; Blood Glucose; Carotid Arteries; Carotid Intima-Media Thickness; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Predictive Value of Tests; Prospective Studies; Pulse Wave Analysis; Recovery of Function; Time Factors; Treatment Outcome; Vascular Stiffness | 2017 |
No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
Topics: Adamantane; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Multicenter Studies as Topic | 2014 |
Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
Topics: Adamantane; Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Male; Nitriles; Oxidative Stress; Pyrrolidines; Rats; Rats, Sprague-Dawley; Vildagliptin | 2012 |